Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)

The summary for the Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional): The overall goal of this initiative is to identify neurophysiological measures potential assays for treatment development research. The funding opportunity announcement (FOA) will support efforts to optimize and evaluate measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data will also reveal assay measures where the performance between preclinical animal species and humans is dissimilar, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. The ultimate practical goal of this FOA is to improve the efficiency of the therapeutic development process by identifying coherence of measures and inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates and thereby hasten the development of more effective treatments for mental disorders.

Federal Grant Title:	Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-23-087
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.242
CFDA Descriptions:	Information not provided
Current Application Deadline:	June 20th, 2025
Original Application Deadline:	June 20th, 2025
Posted Date:	January 13th, 2023
Creation Date:	January 13th, 2023
Archive Date:	July 26th, 2025
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	January 13th, 2023

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: https://grants.nih.gov/grants/guide/pa-files/PAR-23-087.html
Grant Announcement Contact: NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Understanding the Intersection of Social Inequities to Optimize Health and Reduce Health D...; • Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Re...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH...; • Interaction between ARVs and Hormones in HIV and Coinfections (R01 Clinical Trial Optional...; • Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R4...; • Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44...; • Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44])
More Grants from the National Institutes of Health: • Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required); • Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans...; • Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required); • NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional); • NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)